全文获取类型
收费全文 | 14150篇 |
免费 | 1730篇 |
国内免费 | 468篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 498篇 |
妇产科学 | 75篇 |
基础医学 | 3466篇 |
口腔科学 | 95篇 |
临床医学 | 1326篇 |
内科学 | 1495篇 |
皮肤病学 | 264篇 |
神经病学 | 566篇 |
特种医学 | 279篇 |
外国民族医学 | 5篇 |
外科学 | 1606篇 |
综合类 | 1476篇 |
现状与发展 | 8篇 |
预防医学 | 504篇 |
眼科学 | 55篇 |
药学 | 1193篇 |
5篇 | |
中国医学 | 274篇 |
肿瘤学 | 3013篇 |
出版年
2024年 | 53篇 |
2023年 | 323篇 |
2022年 | 620篇 |
2021年 | 822篇 |
2020年 | 709篇 |
2019年 | 650篇 |
2018年 | 734篇 |
2017年 | 722篇 |
2016年 | 672篇 |
2015年 | 582篇 |
2014年 | 800篇 |
2013年 | 1285篇 |
2012年 | 703篇 |
2011年 | 772篇 |
2010年 | 587篇 |
2009年 | 541篇 |
2008年 | 579篇 |
2007年 | 562篇 |
2006年 | 536篇 |
2005年 | 469篇 |
2004年 | 452篇 |
2003年 | 388篇 |
2002年 | 356篇 |
2001年 | 349篇 |
2000年 | 262篇 |
1999年 | 225篇 |
1998年 | 170篇 |
1997年 | 175篇 |
1996年 | 176篇 |
1995年 | 118篇 |
1994年 | 110篇 |
1993年 | 92篇 |
1992年 | 66篇 |
1991年 | 68篇 |
1990年 | 60篇 |
1989年 | 54篇 |
1988年 | 57篇 |
1987年 | 35篇 |
1986年 | 51篇 |
1985年 | 58篇 |
1984年 | 61篇 |
1983年 | 40篇 |
1982年 | 40篇 |
1981年 | 34篇 |
1980年 | 32篇 |
1979年 | 26篇 |
1978年 | 16篇 |
1977年 | 22篇 |
1976年 | 17篇 |
1975年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer cell》2022,40(3):318-334.e9
- Download : Download high-res image (268KB)
- Download : Download full-size image
2.
3.
4.
5.
6.
《药学学报(英文版)》2020,10(3):414-433
The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40–OX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40–OX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40–OX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40–OX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40–OX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of agonist anti-OX40 treatment will be further enhanced. These data collectively suggest great potential for OX40-mediated therapies. 相似文献
7.
Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Masaki Otsuka Osamu Yamasaki Tatsuya Kaji Keiji Iwatsuki Kenji Asagoe 《The Journal of dermatology》2015,42(10):954-961
Sentinel lymph node biopsy (SLNB) is a widely accepted standard procedure for patients with clinically localized melanoma. Melanoma prevalence and Clark's subtype differ between Asians and Caucasians. Here, we evaluated our experience on SLNB for cutaneous melanoma in a Japanese population. SLNB was performed for patients with melanoma between July 2000 and June 2014. We retrospectively analyzed 102 patients regarding association of clinicopathological features with sentinel lymph node (SLN) status, melanoma‐specific survival (MSS) and disease‐free survival (DFS). A positive SLN was significantly associated with primary Breslow thickness. Compared with 43 patients with negative SLN, 59 patients with positive SLN had significantly shorter MSS (5‐year survival rate, 94.3% vs 63.2%; P = 0.0002) and DFS (5‐year survival rate, 92.7% vs 63.4%; P = 0.0004). According to our subgroup analyses, nine patients with positive non‐SLN had significantly shorter MSS compared with 32 patients with negative non‐SLN (5‐year survival rate, 32.4% vs 68.5%; P = 0.0273). The survival of 51 Japanese patients with acral lentiginous melanoma (ALM) was not inferior to the survival of patients with other Clark's subtype. Breslow thickness is an important factor for both MSS and DFS, and the status of SLN is the most predictive prognostic factor in Japanese patients with clinically localized melanomas, as in case of Caucasians. Features of ALM may be different between Asians and Caucasians. 相似文献
8.
9.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献
10.
Breast cancer is the most common malignancy in women worldwide, with a relatively high proportion of patients experiencing resistance to standard treatments. Cellular immunotherapy (CI), which is based on the extraction, modification, and re-infusion of the patient’s immune cells, is showing promising results in these patients. Among CI possible approaches, adoptive cell therapy (ACT) and dendritic cell (DC) vaccination are the most comprehensively explored in both primary/translational research studies and clinical trials. ACT may include the use of tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-, or chimeric antigen receptor (CAR)-engineered T-cells. There are indications suggesting that a biomarker-based approach might be beneficial in effectively selecting breast cancer patients for CI. Here, we sought to provide the current knowledge of CI in breast cancer, focusing on candidate biomarkers, ongoing clinical trials, limitations, and immediate future perspectives. 相似文献